What question did this study set out to answer?

February 22, 2026Clinical Cancer Research

Abstract PS2-04-22: Real world data of primary resistance to cyclin-dependent kinase 4/6 inhibitors treatment in hormone-receptor positive metastatic breast cancer

View Full Paper

Ask AI

Bookmark

Authors

OCO. Cano i CanoCorporació Sanitària Parc Taulí MGM. Fragío GilCorporació Sanitària Parc Taulí ANA. Carrasco NavasCorporació Sanitària Parc Taulí

Discussion

Member takes

Implication

Retrospective analysis finds poor outcomes in patients with primary resistance to CDK4/6 inhibitors in metastatic breast cancer, suggesting treatment challenges.

Key Points

This research aims to analyze the characteristics and outcomes of patients with primary resistance to CDK4/6 inhibitors combined with endocrine therapy in metastatic breast cancer.
Conducted a retrospective observational study on 180 patients treated at Hospital Parc Taulí from 2017 to 2024.
Identified and analyzed 46 patients with primary resistance within this cohort.
Examined clinical, treatment, efficacy, and survival variables.
Median overall survival was 9 months, with varying outcomes based on resistance type.
Patients with primary resistance had a median overall survival of 13 months, while those with secondary resistance had 8 months.
The median progression free survival was 3 months across the cohort, with slight variances based on resistance classifications.

Cite This Study

Cano et al. (2026) studied this question.

synapsesocial.com/papers/699a9dae482488d673cd3aba https://doi.org/10.1158/1557-3265.sabcs25-ps2-04-22

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis finds poor outcomes in patients with primary resistance to CDK4/6 inhibitors in metastatic breast cancer, suggesting treatment challenges.

Abstract PS2-04-22: Real world data of primary resistance to cyclin-dependent kinase 4/6 inhibitors treatment in hormone-receptor positive metastatic breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS2-04-22: Real world data of primary resistance to cyclin-dependent kinase 4/6 inhibitors treatment in hormone-receptor positive metastatic breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider